



To: [redacted]
Cc: [redacted]; [redacted]@cda.nl]; [redacted]@rvo.nl];
 Jonge, H.M. de (Hugo) [redacted]@minvws.nl]; [redacted]@cda.nl]; [redacted]@cda.nl];
 [redacted]@gmail.com]; [redacted]@gmail.com]; [redacted]@amc.uva.nl]; [redacted]@amc.uva.nl]
From: [redacted]
Sent: Fri 6/18/2021 10:32:31 PM
Subject: Re: [redacted] Cobas SARS-CoV-2 Test | Royalty fee proposal
Received: Fri 6/18/2021 10:32:48 PM

Hebben jullie mensen nodig om mails te beantwoorden? Ook daar kan ik jullie mee helpen.

On Thu, 3 Jun 2021 at 16:37, [redacted] <[redacted]@mujo.com> wrote:

P.s mocht je willen dat ik de contracten doorneem en uitzoeken naar de extis zitten weet je me te vinden.

Best,



[redacted]@mujo.com
www.mujo.com

Office [redacted]
WhatsApp [redacted]

Europe
Mujjo Europe B.V.
Nedinscoplein 3, 5912 AP Venlo
The Netherlands

International
Mujjo International B.V.
Nedinscoplein 3, 5912 AP Venlo
The Netherlands



Information in this email, including any attachments, may be privileged, confidential, and is intended exclusively for the addressee(s). The views expressed may not be official policy but the personal views of the originator. If you have received it in error, please notify the sender by return email and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone.

Mujjo is in no way liable for accurate delivery of this email and any errors or omissions in the content of this email message, which may arise as a result of email transmission. In case of abuse, please email us at [abuse \[at\] mujjo \[dot\] com](mailto:abuse[at]mujjo[dot]com). Please note we reserve the right to monitor all email communication through our internal and external networks.

Mujjo is an international trademark of Ndigo Business B.V. (the Netherlands).

On Thu, Jun 3, 2021 at 4:35 PM [5.1.2e](#) <5.1.2e@mujjo.com> wrote:

Dag [5.1.2e](#)


Vernam via [5.1.2e](#) z'n platform dat het niet helemaal lekker is gelopen met de mondkapjes deal;

1. Waar ging het fout?
2. Hoe kunnen we dit in de toekomst voorkomen?
3. Hoe verkopen we dit aan het volk?

Graag er voor zorgen dat het geld terug komt in de staatspot en nuttig besteed wordt.

Best,

[5.1.2e](#)



5.1.2e@mujjo.com
www.mujjo.com

Office [5.1.2e](#)
WhatsApp

Europe
Mujjo Europe B.V.
Nedinscoplein 3, 5912 AP Venlo
The Netherlands

International
Mujjo International B.V.
Nedinscoplein 3, 5912 AP Venlo
The Netherlands



Information in this email, including any attachments, may be privileged, confidential, and is intended exclusively for the addressee(s). The views expressed may not be official policy but the personal views of the originator. If you have

received it in error, please notify the sender by return email and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone.

Mujjo is in no way liable for accurate delivery of this email and any errors or omissions in the content of this email message, which may arise as a result of email transmission. In case of abuse, please email us at abuse [at] mujjo [dot] com. Please note we reserve the right to monitor all email communication through our internal and external networks.

Mujjo is an international trademark of Ndigo Business B.V. (the Netherlands).

On Thu, May 7, 2020 at 11:54 AM [REDACTED] <[REDACTED]> wrote:

Ik connect je met [REDACTED] die over mondkapjes gaat.

Dank

[REDACTED]

From: [REDACTED] <[REDACTED]@mujjo.com>
Sent: Wednesday, May 6, 2020 8:48 PM
To: [REDACTED] <[REDACTED]>; [REDACTED]@minvws.nl
Cc: [REDACTED] <[REDACTED]@[REDACTED].com>; [REDACTED]@volkskeuken.com
Subject: Re: [REDACTED] Cobas SARS-CoV-2 Test | Royalty fee proposal

CAUTION - This email originated from outside [REDACTED]
 Please forward suspicious emails as attachments to [REDACTED]@[REDACTED].com

Boys,

500 mio N95 (FFP2 & FFP3) mondkapjes, binnen 21 dagen is realistisch. Honderden productie faciliteiten in China leggen hun core business plat om medical masks te produceren. Wij kunnen het niet 'verkopen' hh Nederlands (niet medisch) volk opscheppen te schepen met NON-medical masks.

- Wat zijn de huidige qty's & leadtimes?
- Regelen jullie 170 mio medical masks in 21 dagen?

Ik wordt dagelijks dood gegooid door gerenomeerd fabrieken voor productie van N95 masks. Ik maak graag 'kwaad' 170 mio masks over 21 dagen te fixen. All I need is budget en volmacht.

We moeten nu echt de supply chain gaan securen en ons niet laten belemmeren door democratische besluitvorming.

Groet,

5.1.2e

On Mon, 6 Apr 2020 at 10:00, 5.1.2e <5.1.2e@muji.com> wrote:

Goed geregeld boys!

Groetjes,

5.1.2e

On Wed, Apr 1, 2020 at 11:20 PM 5.1.2e <5.1.2e> wrote:

Dank 5.1.2e

We zitten er boven op en zijn al VER gevorderd in 4 dagen

Dank

From: 5.1.2e <5.1.2e@muji.com>
Sent: Friday, March 27, 2020 9:57 AM
To: 5.1.2e <5.1.2e>
Cc: 5.1.2e <5.1.2e@5.1.2e.com>; 5.1.2e @minvws.nl
Subject: Re: 5.1.2e | Cobas SARS-CoV-2 Test | Royalty fee proposal

CAUTION - This email originated from outside 5.1.2e
 Please forward suspicious emails as attachments to 5.1.2e @5.1.2e.com

Morgen 5.1.2e

Waar ligt volgens jou het issue?

Ik zie enkele solutions iz de 5.1.2e uitdaging;

1. EU centrale inkoop en gecontroleerde distributie over lidstaten (+ evt. aspirant);
2. Bij het *ieder lidstaat voor zich principe* vanuit (EU/VN) druk zetten op 5.1.2e voor een fair en transparant distribution (price) policy;
3. Wanneer punt 2 te complex is, dan maar economisch onderhandeling in gaan door een licentievergoeding op

eigen productie, met 100% overheidsgarantie op betaling (geen moeilijke onderhandeling lijkt mij gezien onze Moody's rating).

Last but not least, verder kijken dan **5.1.2e** is er bijvoorbeeld al contact geleged met **5.1.2e** van het International Vaccine Institute, hij heeft first-hand experience met drive-thru test centra in Korea, die (heb zelf geen medische kennis) volgens mij goed werken.

Best,

5.1.2e

5.1.2e [@mujjo.com](mailto:5.1.2e@mujjo.com)

www.mujjo.com

Office

WhatsApp

5.1.2e

Europe

Mujjo Europe B.V.

Nedinscoplein 3, 5912 AP Venlo

The Netherlands

International

Mujjo International B.V.

Nedinscoplein 3, 5912 AP Venlo

The Netherlands

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee(s). The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return email and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone.

Mujjo is in no way liable for accurate delivery of this email and any errors or omissions in the content of this email message, which may arise as a result of email transmission. In case of abuse, please email us at [abuse \[at\] mujjo \[dot\] com](mailto:abuse[at]mujjo[dot]com). Please note we reserve the right to monitor all email communication through our internal and external networks.

Mujjo is an international trademark of Ndigoo Business B.V. (the Netherlands).

On Thu, Mar 26, 2020 at 8:35 PM [REDACTED] <[REDACTED]> wrote:

Dank

Kan je met [REDACTED] bellen

Ik denk niet dat licentie het issue is

[REDACTED]

From: [REDACTED] <[REDACTED]@mujjo.com>
Sent: Thursday, March 26, 2020 6:14 PM
To: [REDACTED] <[REDACTED]>
Cc: [REDACTED] <[\[REDACTED\]@minvws.nl](mailto:[REDACTED]@minvws.nl)>
Subject: Fwd: [REDACTED] Cobas SARS-CoV-2 Test | Royalty fee proposal

CAUTION - This email originated from outside [REDACTED]
Please forward suspicious emails as attachments to [REDACTED] <[\[REDACTED\]@\[REDACTED\].com](mailto:[REDACTED]@[REDACTED].com)>

[REDACTED] fyi; vanmiddag onderstaande voorzet gedaan.

----- Forwarded message -----
From: [REDACTED] <[REDACTED]@mujjo.com>
Date: Thu, Mar 26, 2020 at 5:57 PM
Subject: Re: [REDACTED] Cobas SARS-CoV-2 Test | Royalty fee proposal
To: <[REDACTED]@roche.com>
Cc: <[REDACTED]@minvws.nl>

A response before tomorrow morning 10 AM would be appreciated, so we can discuss this in the council of ministers.

Thanks, [REDACTED]

On Thu, Mar 26, 2020 at 2:37 PM [REDACTED] <[REDACTED]@muji.com> wrote:

Hi [REDACTED]

Urgently needing a royalty fee proposal for Cobas SARS-CoV-2 test kit production, in the Netherlands, for the Dutch healthcare.

Please share a draft agreement and royalty conditions so we can tackle the shortage asap.

Yours Sincerely,

[REDACTED]

[REDACTED]@muji.com
www.muji.com

Office [REDACTED]
WhatsApp [REDACTED]

Europe
Muji Europe B.V.
Nedinscopein 3, 5912 AP Venlo
The Netherlands

International
Muji International B.V.
Nedinscopein 3, 5912 AP Venlo
The Netherlands

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee(s). The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return email and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone.

Mujjo is in no way liable for accurate delivery of this email and any errors or omissions in the content of this email message, which may arise as a result of email transmission. In case of abuse, please email us at abuse [at] mujjo [dot] com. Please note we reserve the right to monitor all email communication through our internal and external networks.

Mujjo is an international trademark of Ndigo Business B.V. (the Netherlands).

DISCLAIMER:

This e-mail is for the intended recipient only.

If you have received it by mistake please let us know by reply and then delete it from your system; access, disclosure, copying, distribution or reliance on any of it by anyone else is prohibited.

If you as intended recipient have received this e-mail incorrectly, please notify the sender (via e-mail) immediately.

DISCLAIMER:

This e-mail is for the intended recipient only.

If you have received it by mistake please let us know by reply and then delete it from your system; access, disclosure, copying, distribution or reliance on any of it by anyone else is prohibited.

If you as intended recipient have received this e-mail incorrectly, please notify the sender (via e-mail) immediately.

DISCLAIMER:

This e-mail is for the intended recipient only.


If you have received it by mistake please let us know by reply and then delete it from your system; access, disclosure, copying, distribution or reliance on any of it by anyone else is prohibited.


If you as intended recipient have received this e-mail incorrectly, please notify the sender (via e-mail) immediately.

--

Best,

5.1.2e






Office
WhatsApp 5.1.2e

Europe

Mujjo Europe B.V.
Nedinscopein 3, 5912 AP Venlo
The Netherlands

International

Mujjo International B.V.
Nedinscopein 3, 5912 AP Venlo
The Netherlands



Information in this email, including any attachments, may be privileged, confidential, and is intended exclusively for the addressee(s). The views expressed may not be official policy but the personal views of the originator. If you have received it in error, please notify the sender by return email and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone.

Mujjo is in no way liable for accurate delivery of this email and any errors or omissions in the content of this email message, which may arise as a result of email transmission. In case of abuse, please email us at abuse [at] mujo [dot] com. Please note we reserve the right to monitor all email communication through our internal and external networks.

Mujjo is an international trademark of Ndigo Business B.V. (the Netherlands).